Related Experiment Videos
Antiviral effects of rhIFN-alpha 1 against seven influenza viruses
1Department of Physiology, China Pharmaceutical University, Nanjing, China. phamcol@mails.cpu.edu.cn
Aim:
To study the antiviral effects of rhIFN-alpha 1 (Chinese silkworm gene recombinant interferon alpha 1) on 7 influenza viruses in MDCK cells and in mouse pneumonia caused by PR8 virus.
Methods:
100TCID50 virus (H1N1, H2N2, H3N3, type B, type C, clinical A1, and clinical B) were inoculated into MDCK cells, PR8 viruses were dropped nasally in mice, the antiviral effects of rhIFN-alpha 1 were observed.
Results:
The minimal effective concentrations of rhIFN-alpha 1 against these 7 influenza viruses were 12.5, 25, 50, 25, 12.5, 25, and 12.5 kU.L-1, respectively. The infectious therapeutic indices of rhIFN-alpha 1 to these viruses in MDCK cells were 8 x 10(3), 4 x 10(3), 2 x 10(3), 4 x 10(3), 8 x 10(3), 4 x 10(3), and 8 x 10(3), respectively. The inhibitory indices of rhIFN-alpha 1 to the 7 influenza viruses in MDCK cells were 3.6, 4.7, 3.5, 3.3, 3.9, 4.6, and 3.5, respectively. The rhIFN-alpha 1 inhibited the intracellular replication of influenza viruses effectively, but did not kill viruses directly. The rhIFN-alpha 1 prolonged the life span of mice infected with pneumonia by influenza virus A strain PR8 to 94.2%-132.7%. It inhibited the inflammation and hyperplasia of interstitial fibers, and decreased the virus titer. The inhibitory rates of rhIFN-alpha 1 to pulmonary-indice were 14.8%-37.4%.
Conclusion:
rhIFN-alpha 1 inhibited the proliferation of influenza virus and improved the symptom of mouse pneumonia caused by influenza virus.
Insights
Recombinant human interferon alpha 1 (rhIFN-alpha 1) effectively inhibited influenza virus replication in cell cultures and reduced pneumonia symptoms in mice. This study highlights rhIFN-alpha 1
Area of Science:
- Virology
- Immunology
- Biotechnology
Background:
- Influenza viruses pose a significant global health threat.
- Development of effective antiviral therapies remains crucial.
Purpose of the Study:
- To evaluate the antiviral efficacy of recombinant human interferon alpha 1 (rhIFN-alpha 1) against seven strains of influenza viruses in vitro.
- To assess the therapeutic potential of rhIFN-alpha 1 in a mouse model of influenza A virus (PR8 strain) induced pneumonia.
Main Methods:
- In vitro antiviral activity was tested in MDCK cells infected with various influenza virus strains (H1N1, H2N2, H3N3, B, C, and clinical isolates).
- In vivo efficacy was studied in mice infected intranasally with PR8 influenza virus, with rhIFN-alpha 1 administration.
- Key parameters measured included minimal effective concentration, infectious therapeutic index, inhibitory index, viral replication, survival rates, and pulmonary pathology.
Main Results:
- rhIFN-alpha 1 demonstrated potent antiviral activity against all tested influenza viruses in MDCK cells, with minimal effective concentrations ranging from 12.5 to 50 kU/L.
- The compound effectively inhibited intracellular viral replication without direct virucidal effects.
- In the mouse model, rhIFN-alpha 1 significantly improved survival rates (94.2%-132.7%), reduced lung inflammation, and decreased viral titers.
Conclusions:
- rhIFN-alpha 1 exhibits significant antiviral properties against a broad spectrum of influenza viruses.
- rhIFN-alpha 1 demonstrates therapeutic potential for managing influenza virus infections and associated pneumonia.